Regardless of the limitations, the EMMY trial represents an important step forward for SGLT2 inhibitors in the management of post-MI heart failure and increases the optimism that these drugs may provide clinical benefit to the post-MI population. This evidence concerns the gene SLC5A2 and heart failure.